Abstract
Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Anaplastic Lymphoma Kinase
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / enzymology
-
Carcinoma, Non-Small-Cell Lung / metabolism
-
Crizotinib
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / metabolism
-
Male
-
Meningeal Carcinomatosis / drug therapy*
-
Meningeal Carcinomatosis / metabolism
-
Methotrexate / administration & dosage
-
Middle Aged
-
Protein Kinase Inhibitors / administration & dosage
-
Pyrazoles / administration & dosage
-
Pyridines / administration & dosage
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Receptor Protein-Tyrosine Kinases / metabolism
Substances
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyridines
-
Crizotinib
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases
-
Methotrexate